PT -期刊文章盟van Bragt工作J.M.H. AU -爱德考克,伊恩m . AU -贝尔,伊丽莎白收听距离盟——Braunstahl Gert-Jan盟——十Brinke安非盟-巴斯比约翰AU - Canonica,乔治·w . AU -曹,回族非盟- Chung, Kian风扇盟——Csoma Zsuzsanna AU - Dahlen barbroandreasson盟——Davin伊丽莎白AU -汉森,Susanne AU - Heffler,恩里科盟-霍Ildiko AU -科恩,斯蒂芬妮AU -科特,马克西姆AU -库纳,彼得亚雷盟- Kwon Namhee AU -路易斯,Renaud盟——广场,韦森特盟——Porsbjerg Celeste盟——Ramos-Barbon大卫AU -理查兹利b . AU -Škrgat,萨比娜盟,是雅各k . AU - Vijverberg Susanne J.H.盟——Weersink Els J.M.盟——Yasinska Valentyna盟——赌注,斯科特·s . AU -也有rako AU - Maitland-van der Zee，Anke h . TI -特点和治疗方案在人急剧严重哮喘注册援助- 10.1183/13993003.01163 -2019 DP - 2020年1月01 TA -欧洲呼吸杂志》第六PG - 1901163 - 55 IP - 1 4099 - //www.qdcxjkg.com/content/55/1/1901163.short 4100 - //www.qdcxjkg.com/content/55/1/1901163.full所以欧元和J20201月1日;55 AB -欧洲严重哮喘患者的特征和治疗尚不清楚，但两者可能存在差异。这是欧洲呼吸学会重度异质性哮喘研究合作项目，以患者为中心(SH188bet官网地址ARP)临床研究合作项目的第一项研究，旨在探索这些变化。因此，我们的目的是在开始使用生物制剂之前，比较欧洲重症哮喘注册和治疗患者的特征。这是一项横断面回顾性分析，收集了11个国家重症哮喘登记数据，并将SHARP与已建立的患者数据库相结合。对3236例患者的数据分析显示，在特征和生活方式因素方面存在许多差异。目前吸烟者的范围从0%(波兰和瑞典)到9.5%(比利时)，平均体重指数从26.2(意大利)到30.6 kg·m - 2(英国)，预计1%前支气管扩张器强迫呼气量的最大差异为20.9%(荷兰和匈牙利)。 Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.The severe asthma population in Europe is heterogeneous and differs in clinical characteristics and treatment. Harmonisation across registries and guidelines is needed and requires collection of same data across cohorts to enable future research in SHARP. http://bit.ly/2krxHPf